Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12
E Thervet, D Anglicheau, B King, MH Schlageter… - …, 2003 - journals.lww.com
Background. Tacrolimus pharmacokinetic characteristics vary greatly among individuals.
Tacrolimus is a substrate of cytochrome P450 (CYP), of subfamily CYP3A. CYP3A activity is …
Tacrolimus is a substrate of cytochrome P450 (CYP), of subfamily CYP3A. CYP3A activity is …
A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients
L Elens, R Bouamar, DA Hesselink, V Haufroid… - Clinical …, 2011 - academic.oup.com
BACKGROUND Tacrolimus (Tac) is a potent immunosuppressant with considerable toxicity.
Tac pharmacokinetics varies between individuals and thus complicates its use in preventing …
Tac pharmacokinetics varies between individuals and thus complicates its use in preventing …
[HTML][HTML] Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype
N Pallet, I Etienne, M Buchler, E Bailly… - American Journal of …, 2016 - Elsevier
Pretransplantation adaptation of the daily dose of tacrolimus to CYP3A5 genotype is
associated with improved achievement of target trough concentration (C 0), but whether this …
associated with improved achievement of target trough concentration (C 0), but whether this …
Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal …
BC Sallustio, BD Noll, R Hu, DT Barratt… - British Journal of …, 2021 - Wiley Online Library
Aims Long‐term use of the immunosuppressant tacrolimus is limited by nephrotoxicity.
Following renal transplantation, the risk of nephrotoxicity may be determined more by …
Following renal transplantation, the risk of nephrotoxicity may be determined more by …
[HTML][HTML] Pharmacogenetics of tacrolimus: ready for clinical translation?
E Coto, B Tavira, B Suárez-Álvarez… - Kidney international …, 2011 - Elsevier
Tacrolimus (Tac) exhibits an interindividual pharmacokinetic variability that affects the dose
required to reach the target concentration in blood. Tac is metabolized by two enzymes of …
required to reach the target concentration in blood. Tac is metabolized by two enzymes of …
Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center
HC Kim, EA Hwang, SY Han, SB Park, HT Kim… - Transplantation …, 2004 - Elsevier
INTRODUCTION: The 1-year results of the phase III US Multicenter Trial comparing
tacrolimus-and cyclosporine (Sandimmun)-based immunosuppressive therapy in kidney …
tacrolimus-and cyclosporine (Sandimmun)-based immunosuppressive therapy in kidney …
The combination of CYP3A4* 22 and CYP3A5* 3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation
N Lloberas, L Elens, I Llaudó, A Padullés… - Pharmacogenetics …, 2017 - journals.lww.com
Results EM had an 88% lower dose-adjusted C 0 compared with IM. PM had a 26% higher
dose-adjusted C 0 compared with IM. The percentage of patients with supratherapeutic Tac …
dose-adjusted C 0 compared with IM. The percentage of patients with supratherapeutic Tac …
Avoiding tacrolimus underexposure and overexposure with a dosing algorithm for renal transplant recipients: a single arm prospective intervention trial
MI Francke, LM Andrews, HL Le… - Clinical …, 2021 - Wiley Online Library
Bodyweight‐based tacrolimus dosing followed by therapeutic drug monitoring is standard
clinical care after renal transplantation. However, after transplantation, a meager 38% of …
clinical care after renal transplantation. However, after transplantation, a meager 38% of …
Influence of CYP3A5 Genetic Polymorphism on Tacrolimus Daily Dose Requirements and Acute Rejection in Renal Graft Recipients
L Quteineh, C Verstuyft, V Furlan… - Basic & clinical …, 2008 - Wiley Online Library
Tacrolimus is a widely used immunosuppressive drug in organ transplantation. Its oral
bioavailability varies greatly between individuals, and it is a substrate of cytochrome P450 …
bioavailability varies greatly between individuals, and it is a substrate of cytochrome P450 …
CYP3A5 *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant …
Purpose We assessed reported associations of CYP3A5* 1 allele with a delay in achieving
target tacrolimus concentrations, and occurrence of biopsy-confirmed subclinical acute …
target tacrolimus concentrations, and occurrence of biopsy-confirmed subclinical acute …